Merck

Merck KGaA focuses its oncology research on the development of novel therapies that specifically target cancer cells. The monoclonal antibody Erbitux® (cetuximab), Merck's first oncology product, specifically blocks the epidermal growth factor receptor (EGFR). Erbitux enhances the effect of chemotherapy and raditation. Merck has also acquired the rights for the oral cancer treatment UFT® (tegafur-uracil).

Merck’s oncology research activities focus on identifying compounds that specifically interfere with one or more of the key cellular processes or pathways which influence the growth and spread of cancer cells. The resulting range of new compounds, including the humanized EGFR targeting monoclonal antibody matuzumab, the cancer vaccine Stimuvax® (formerly referred to as L-BLP25), the angiogenesis inhibitor cilengitide and several immunocytokines, are currently undergoing clinical development.

For further information visit www.merck.de